Core Viewpoint - The company successfully completed a new H-share placement, raising approximately HKD 562.1 million, with 40% of the proceeds allocated to the development of data and AI in the medical imaging sector, indicating strong recognition from long-term capital for its "data-AI-scenario" ecosystem [1] Group 1: Company Developments - The company plans to issue 35 million shares, with the net proceeds aimed at enhancing its capabilities in medical imaging data mining, annotation, and cleaning, as well as developing an AI application platform [1] - The company has established a service network covering 115 imaging centers, generating nearly 10 million new medical imaging data annually, making it one of the largest and fastest-growing medical imaging databases in China [1] - The company has incubated the "MIIA 觅芽" model, which is the world's first full-modal, full-process medical imaging base model [1] Group 2: Market Trends - The first AI product designed by body part is set to launch in Q3 2025, with plans to accelerate the deployment of multi-part imaging large models, creating a commercial loop of "data feeding algorithms, algorithms feeding scenarios" [2] - The AI medical sector is becoming increasingly active, with companies like Tempus AI seeing significant stock price increases, indicating a growing interest in AI healthcare solutions [2] - Fund managers predict a high probability of a rebound in AI medical stocks in the second half of the year, with increasing attention from capital towards companies in this sector [3] Group 3: Strategic Focus - The company will focus on enhancing its medical imaging data service capabilities and AI application platform development, investing in advanced algorithms and professional talent to improve data processing efficiency and accuracy [3] - The company aims to support the development of an integrated AI application platform covering the entire medical imaging process, enhancing diagnostic efficiency and accuracy for medical institutions [3] - Following the completion of the placement, the company's shareholder structure will be optimized, increasing liquidity and positioning it as a benchmark enterprise in the global medical imaging service and AI healthcare integration field [3]

Core Viewpoint - The company successfully completed a new H-share placement, issuing 35 million shares and raising approximately HKD 562.1 million, reflecting strong market confidence in its "data-AI-scenario" ecosystem and strategic value [1][2] Group 1: Financial Performance and Market Response - The placement attracted significant interest from long-term and medical specialty funds, resulting in multiple times oversubscription, indicating deep market recognition of the company's core value and growth potential [1][2] - The funds raised will be directed towards three key areas, providing strong momentum for the company's long-term development [2] Group 2: Business Expansion and Strategic Partnerships - The company has established a service network covering 115 imaging centers, with nearly 10 million new medical imaging data cases annually, making it one of the largest and fastest-growing medical imaging databases in China [1] - The company is accelerating its overseas strategy, having formed an alliance with Hong Kong's Yisi Health to establish imaging centers, with plans to expand into new markets such as Singapore, Malaysia, and the Middle East by H2 2025 [2] Group 3: Technological Advancements - The company has launched the world's first full-modal, full-process medical imaging foundation model, "MIIA Miya," with the first AI product set to be released in Q3 2025, enhancing its competitive edge in the medical AI sector [1] - The business model combines data-driven algorithms with practical applications, creating a commercial loop that is highly valued by international capital [1]